文献速递艾滋病与性传播感染

长效卡博特韦与利匹韦林每2个月给药一次治疗1型人类免疫缺陷病毒感染成人:ATLAS-2M随机、开放标签、3b期非劣效性研究152周结果

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
PubMed 文献 · Clin Infect Dis · 2023-01-01

ATLAS-2M研究第152周结果显示,病毒学抑制的HIV-1感染者接受长效卡博特韦+利匹韦林每8周或每4周肌注,每8周组HIV-1 RNA≥50拷贝/mL比例为2.7%(n=14),每4周组为1.0%(n=5),调整治疗差异1.7%(95%CI:0.1-3.3%),符合4%非劣效界值。87%参与者维持HIV-1 RNA<50拷贝/mL,安全性特征与第48周相比无新信号。

要点

  • 每8周给药方案在维持病毒学抑制方面非劣效于每4周方案。
  • 第152周87%参与者维持HIV-1 RNA<50拷贝/mL。
  • 每8周组确认病毒学失败12例(2.3%),每4周组2例(0.4%)。

核心结论

  • 每8周或每4周给予长效卡博特韦+利匹韦林约3年可持续维持病毒学抑制,证实其作为完整方案维持HIV-1病毒学抑制的长期疗效、安全性和耐受性。

研究设计与样本

  • ATLAS-2M为3b期、随机、多中心研究,评估每8周与每4周给予长效卡博特韦+利匹韦林的有效性和安全性。
  • 共1045例病毒学抑制(HIV-1 RNA<50拷贝/mL)的HIV-1感染者接受长效卡博特韦+利匹韦林,每8周组n=522,每4周组n=523。

主要发现

  • 每8周组HIV-1 RNA≥50拷贝/mL比例为2.7%(n=14),每4周组为1.0%(n=5),调整治疗差异1.7%(95%CI:0.1-3.3%),符合4%非劣效界值。
  • 第152周时,87%参与者维持HIV-1 RNA<50拷贝/mL(每8周组87%[n=456],每4周组86%[n=449])。
  • 每8周组12例(2.3%)参与者发生确认病毒学失败,每4周组2例(0.4%)。
  • 发生确认病毒学失败的参与者中,分别有8例和10例出现对利匹韦林和整合酶抑制剂的治疗 emergent 耐药相关突变。
  • 安全性特征相当,自第48周以来未观察到新的安全性信号。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cabotegravir (CAB) + rilpivirine (RPV) dosed intramuscularly monthly or every 2 months is a complete, long-acting (LA) regimen for the maintenance of HIV-1 virologic suppression. Here, we report the antiretroviral therapy as long acting suppression (ATLAS)-2M study week 152 results. METHODS: ATLAS-2M is a phase 3b, randomized, multicenter study assessing the efficacy and safety of CAB+RPV LA every 8 weeks (Q8W) versus every 4 weeks (Q4W). Virologically suppressed (HIV-1 RNA <50 copies/mL) individuals were randomized to receive CAB+RPV LA Q8W or Q4W. Endpoints included the proportion of participants with plasma HIV-1 RNA ≥50 copies/mL and <50 copies/mL, incidence of confirmed virologic failure (CVF; 2 consecutive measurements ≥200 copies/mL), safety, and tolerability. RESULTS: A total of 1045 participants received CAB+RPV LA (Q8W, n = 522; Q4W, n = 523). CAB+RPV LA Q8W demonstrated noninferior efficacy versus Q4W dosing, with 2.7% (n = 14) and 1.0% (n = 5) of participants having HIV-1 RNA ≥50 copies/mL, respectively, with adjusted treatment difference being 1.7% (95% CI: 0.1-3.3%), meeting the 4% noninferiority threshold. At week 152, 87% of participants maintained HIV-1 RNA <50 copies/mL (Q8W, 87% [n = 456]; Q4W, 86% [n = 449]). Overall, 12 (2.3%) participants in the Q8W arm and 2 (0.4%) in the Q4W arm had CVF. Eight and 10 participants with CVF had treatment-emergent, resistance-associated mutations to RPV and integrase inhibitors, respectively. Safety profiles were comparable, with no new safety signals observed since week 48. CONCLUSIONS: These data demonstrate virologic suppression durability with CAB+RPV LA Q8W or Q4W for ∼3 years and confirm long-term efficacy, safety, and tolerability of CAB+RPV LA as a complete regimen to maintain HIV-1 virologic suppression.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Overton ET, Richmond G, Rizzardini G, et al. Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study. Clin Infect Dis. 2023. PMID: 36660819. doi:10.1093/cid/ciad020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。